Your browser doesn't support javascript.
loading
Reconciling Discordance Between Prostate Biopsy Histology and Magnetic Resonance Imaging Suspicion - Implementation of a Quality Improvement Protocol of Imaging Re-review and Reverse-fusion Target Analysis.
Kotamarti, Srinath; Gupta, Rajan T; Wang, Bangchen; Séguier, Denis; Michael, Zoe; Zhang, Dylan; Abern, Michael R; Huang, Jiaoti; Polascik, Thomas J.
Afiliação
  • Kotamarti S; Division of Urology, Duke University Medical Center, Durham, NC, United States. Electronic address: srinath.kotamarti@duke.edu.
  • Gupta RT; Division of Urology, Duke University Medical Center, Durham, NC, United States; Department of Radiology, Duke University Medical Center, Durham, NC, United States; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, United States.
  • Wang B; Department of Pathology, Duke University Medical Center, Durham, NC, United States.
  • Séguier D; Division of Urology, Duke University Medical Center, Durham, NC, United States; Department of Urology, Lille University, Lille, France.
  • Michael Z; Division of Urology, Duke University Medical Center, Durham, NC, United States.
  • Zhang D; Department of Radiology, Duke University Medical Center, Durham, NC, United States.
  • Abern MR; Division of Urology, Duke University Medical Center, Durham, NC, United States; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, United States.
  • Huang J; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, United States; Department of Pathology, Duke University Medical Center, Durham, NC, United States.
  • Polascik TJ; Division of Urology, Duke University Medical Center, Durham, NC, United States; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, United States.
Eur Urol Oncol ; 5(5): 483-493, 2022 10.
Article em En | MEDLINE | ID: mdl-35879190
There is uncertainty with how to proceed when targeted prostate biopsy of suspicious multiparametric magnetic resonance imaging (mpMRI) lesions return without clinically significant prostate cancer (csPCa). While possible, there are error sources that could contribute to such discordance including the mpMRI read, mpMRI-ultrasound fusion, biopsy technique, and histologic classification. Consequences are potentially significant; mistakenly missing csPCa can lead to delays in curative treatment. Conversely, in cases of incorrect mpMRI interpretation, the patient may be subjected to unnecessary workup/burden. At our institution, we implemented a quality improvement (QI) initiative triggered after a discordant case occurs. This multidisciplinary review process incorporates mpMRI re-review and assessment of accurate lesion-sampling, termed "reverse-fusion." Herein, we describe the protocol, present sample cases, and discuss clinical implications.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Próstata / Neoplasias da Próstata Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Próstata / Neoplasias da Próstata Idioma: En Ano de publicação: 2022 Tipo de documento: Article